Offshoring Biomanufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Offshoring Biomanufacturing
China rises to the top as a destination for international outsourcing.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 7, Issue 9

Other effects

Along with biopharmaceutical manufacturing growth in Asia comes opportunity for vendors, such as providers of equipment and consumables. The BioPlan study shows that more than half of respondents specifically sell to India and China, and 38.7% of all vendors sell in other Asian markets (2).


Figure 2: Select factors creating future capacity constraints.
The growth of emerging countries also contribute to a tightening of the global scientific labor markets. This year's survey showed that concerns over hiring are increasing as the global economic downturn stabilizes. Expectations of constraints due to the "inability to hire new, experienced scientific staff" jumped from 19.1% of respondents in 2010 to 27.6% in 2011. The survey, which compiled the factors likely to create biopharmaceutical production constraints by 2015, found that facility constraints (48.6%) topped the list, followed by the "inability to hire new, experienced technical and production staff" (31%) and the "physical capacity of downstream purification equipment" (28.1%) (see Figure 2). This tightening for experienced bioprocessing specialists may be due to expansions in growth of operations and further exacerbated by specialists increasingly spread out over a growing number of biopharmaceutical companies worldwide.

Eric Langer is president of BioPlan Associates, tel. 301.921.5979,
, and a periodic contributor to Outsourcing Outlook.

References

1. BioPlan Associates, 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production: A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations (Rockville, MD), April 2011.

2. BioPlan Associates, Top 1000 Global Biopharmaceutical Facilities Index, http://www.top1000bio.com/index.asp, accessed June 20, 2011.

3. WHO, "China's State Food and Drug Administration Gets WHO Approval for Vaccine Regulatory System" Press Release, Mar. 1, 2011.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here